Index

acute myelogenous leukemia (AML) 60–61
adaptive resistance 232, 236–237, 239, 245
AML, *see* acute myelogenous leukemia
analytical performance 28, 34, 38–39, 42–43
analytical sensitivity 36–37, 43, 75–76
analytical validity 29, 34, 174–175
assay platforms 16, 18
assay providers 83

bacteria 64–65, 113
bacteria detection 113
BCR, *see* breakpoint cluster region
bioinformatics 78, 89, 113, 121
biomarker-guided designs 174
biomarker multiplexing 78–79, 89
biomarker profiling 73–74, 90
biomarkers 1–2, 16, 21–23, 75, 78–79, 142–145, 173–181, 193, 208
bone marrow 60, 207, 209, 211, 217
bovine serum albumin (BSA) 151, 208
breakpoint cluster region (BCR) 163, 209, 217
breast cancer 2, 16-17, 20–22, 61–62, 118, 144, 206
breast carcinoma 134–135, 141, 161
BSA, *see* bovine serum albumin

cancer 20–22, 58, 61–62, 73–74, 76, 79–80, 82, 84, 86, 88–90, 139–141, 164, 181, 196, 207–208
  endometrial 196
  human 2, 20–21, 23, 149
  ovarian 21, 23
  pancreatic 75
cancer cells 61–62, 154–159
  gastric 63, 131
  oncogene-addicted 237, 239
cancer driver genes 19
cancer patients 1, 28, 49–50, 119, 164, 206
  cell lung 117
  metastatic colorectal 98, 101
  pancreatic 75, 80
CancerSeek Test 80, 89–90
cancer therapies 205
cancer types 2, 16–17, 20–21, 80, 82, 141, 145
carcinoma cells 130–132
cell lung cancer 21, 118, 139–141
cells 66, 81, 130–132, 154–155, 158–161, 164, 218, 233, 238
  animal 155
  normal 150, 161
  red blood 152, 154
cell scraper 156–157

chemotherapy, platinum-based 233–234
chromosome 22–23, 163, 166, 168, 209, 211
chronic myeloid leukemia (CML) 60–61, 163–166, 205–211, 213–222
circulating tumor cells (CTCs) 62, 193
CLIA, *see* Clinical Laboratory Improvement Amendments
clinical laboratories 29, 48, 58, 102, 105, 218–219
Clinical Laboratory Improvement Amendments (CLIA) 28, 30, 32–48, 50
clinical samples 19, 47, 102, 118, 216–217, 220
clinical trials 17, 84, 140, 144, 169, 173, 176, 182, 195, 241
clinical validity 29, 34, 174
CML, *see* chronic myeloid leukemia
colorectal 20, 159
colorectal cancer (CRC) 21, 23, 62–63, 98–99, 101, 118, 134, 141, 151, 156, 158–160, 175, 184, 189–198
combined positive score (CPS) 138–140
companies, commercial 28, 120
companion diagnostics 1–2, 18, 27–28, 32–34, 55–56, 97–98, 129, 133–134, 138–139, 141, 149–150, 163–164, 166–169, 173, 189–190
complementary diagnostics 82, 129–131, 133, 138–141, 143, 145
complementary targets 215, 217
control arm 177–178
control treatment 177–178, 180
CPS, *see* combined positive score
CRC, *see* colorectal cancer
CRT, *see* cyclic reversible termination
CTCs, *see* circulating tumor cells
cyclic reversible termination (CRT) 99–101

deep molecular response (DMR) 211, 213, 220–221
design 29, 44, 174–176, 180–184, 208, 214, 216, 218
  adaptive 182
  biomarker-strategy 178–179
  control arm 177–179
  enrichment 174–176
  marker-stratified 175–176, 179–180
  single-arm 180
detection 18, 22, 32–33, 36, 41, 43, 56, 61, 64, 75, 79, 205, 214–215, 217, 241–244
  deletion 22–23
devices 1, 28, 30–31, 76, 82–84, 104, 218
  predicate 31, 83, 85
diagnostic assays 49, 129, 134
diagnostic devices 27, 87, 89, 173
disease 20–21, 28, 58, 60–63, 74–75, 79, 89–90, 120, 166, 168, 184, 189, 197, 206–209, 220
  infectious 55, 58, 63–66
dispase 152, 158–160
DMEM, *see* Dulbeccos Modified Eagle's medium
DMR, *see* deep molecular response
Dulbeccos Modified Eagle's medium (DMEM) 150–152

early detection 79–80, 82, 90, 208
EGFR, *see* epidermal growth factor receptor

epidermal growth factor receptor (EGFR) 18, 22–23, 98, 116, 129, 142, 190–191, 193, 206, 232–239, 242, 244
epithelial cells 159
erlotinib 99, 176, 206, 233–234, 236–241, 244
error rate 40, 102, 104–105
  high 107, 110
exome sequencing 116–117, 121
experimental treatment 174–177, 179–181, 184

FFPE, *see* formalin-fixed paraffin-embedded
fibroblasts 155–156, 158–159, 161
FISH, *see* fluorescence in situ hybridization
flow cell 100–101, 103, 109
fluorescence 56–57, 110, 208, 214
fluorescence in situ hybridization (FISH) 17, 22–23, 116–117, 121, 132–133, 166, 197, 211, 241–242
fluorophores 57, 101, 108, 110, 215
formalin-fixed paraffin-embedded (FFPE) 46, 89, 102, 131–132, 166–168
fusion detection 16, 20, 31, 115–118
fusion genes 60, 207, 242

gastric cancer 21, 62–63, 132, 135, 144
gastric carcinoma 134–135, 138, 140, 142
gefitinib 32, 206, 233–234, 239, 241, 244
gene expression 56, 58, 61, 178
gene fusions 163, 165, 167–168, 241–243
  oncogenic 163–164, 166
genes 18–20, 32–33, 38, 49–50, 56–57, 59–61, 63–66, 79–81, 97–99, 102–103, 116, 119–120, 163–168, 209–210, 242
  cancer-associated 167–168
  multiple 16, 19, 22, 62, 119, 244
  single 61–62, 116
genome 35, 38, 79, 99, 167–168
genomics 19, 30, 58, 80, 89
gold nanoparticles 205–206, 208
growth medium 151–152, 156–158

hairpin structure 215–216, 222
hematologic malignancies 21–22, 40–41, 164
hybridization 103, 117, 132, 215–217

ICP, *see* immune cells present
imatinib 129, 165, 207, 210, 213, 221
immune cells 130–132, 138–140
immune cells present (ICP) 139
individuals, biomarker-negative 175–176
infections 64–65
insertions 18, 36, 98, 102, 107, 114
in situ hybridization (ISH) 17, 22, 76, 116–118, 130–133, 142–143, 166, 197, 211, 241
insulin 150–151
intratumoral heterogeneity 131, 135, 140
ISH, *see* in situ hybridization

kinase 164, 241
kinase inhibitors, tyrosine 165, 206, 210

laboratory developed tests (LDTs) 28–31, 49–50
laboratory information management system (LIMS) 42, 46
LDTs, *see* laboratory developed tests
leukemia patients 217, 220
limit of detection (LOD) 36–37, 43, 75
LIMS, *see* laboratory information management system
liquid biopsies 39, 89–90, 102, 232, 241, 243, 245
LOD, *see* limit of detection
lung cancer 20, 58–60, 176, 232, 238
  early stage 59
  non–small-cell 99, 138–139, 176, 231
lymph node invasion 61, 63

MAF, *see* minor allele frequency
marker-based strategy 177–179
marker-based strategy arm 177–179
marker-strategy designs 174, 176–178
mass spectrometry (MS) 74, 90, 205, 213–214
MDR, *see* medical device regulations
medical device regulations (MDR) 83
medical devices 1, 28, 30–31, 33, 49, 74–76, 81–84, 87
metastatic colorectal cancer 118, 134, 175
microreactors 104, 106
minimal residual disease (MRD) 40, 60–61, 207, 214
minor allele frequency (MAF) 19, 35, 37, 39–40, 43
molecular analysis 183, 190, 241, 243, 245
molecular diagnostics 28, 33, 205–206, 208–211, 214, 216, 218–220, 222
MRD, *see* minimal residual disease
MS, *see* mass spectrometry
mutation detection 18, 116
  somatic 42, 115
mycobacteria 64–65

nanopore 110–111
nanotechnology 206–207, 220, 222
National Comprehensive Cancer Network (NCCN) 88, 190, 211
NCCN, *see* National Comprehensive Cancer Network
next-generation sequencing (NGS) 17–19, 28, 30–31, 34–39, 41, 74, 85–86, 97–112, 114, 116–121, 130, 142, 166–167, 192–193, 241–242
NGS, *see* next-generation sequencing
nivolumab 76, 129, 139
non–small-cell lung cancer (NSCLC) 19–23, 59, 86, 138, 165–168, 178, 231–233, 235–236, 240–244
non–small-cell lung cancer patients 117, 206
novel fusion types 18, 117
NSCLC, *see* non–small-cell lung cancer
nucleotides 100–102, 107–108, 114
  fluorophore-labeled 101, 103

objective response rate (ORR) 233–234
oncogenic fusions 164–169
oncology 46, 55, 58–59, 61, 76, 165, 174, 231
oncology drugs 2, 23
ORR, *see* objective response rate
osimertinib 99, 234–235, 241
ovarian cancer 20, 98, 116, 118

pathology laboratories 130–131, 134–135, 138, 140, 142–144
PBS, *see* phosphate buffered saline
PCR, *see* polymerase chain reaction
  emulsion 104, 106, 108
personalized medicine 129–130, 132, 134, 140, 142, 144, 207, 232
PFS, *see* progression-free survival
phosphate buffered saline (PBS) 152–154, 157
polymerase chain reaction (PCR) 17–18, 22, 55–57, 65–66, 76, 100, 114, 130, 191, 241
precision diagnostics 73–74, 76, 78, 80, 82, 84–86, 88–90, 206
precision medicine 1–2, 18, 20, 22–24, 27, 50, 67, 97–100, 102, 104–106, 120, 183, 185, 189–190, 196–198
predictive biomarkers 142–143, 178, 191, 232–233, 241
primers 18, 47, 56–57, 167, 242
proficiency testing (PT) 41, 50, 144
prognosis 59–62, 165, 189, 196, 207, 213, 221
prognostic 59, 74, 80–81, 89, 193
progression-free survival (PFS) 233–234, 239, 245
proliferation, cell 164, 193, 235, 237, 239
proteomics 58, 74, 80, 87–89
proteomics technologies 74, 79–80, 87, 90
PT, *see* proficiency testing

RCA, *see* rolling circle amplification
reagents 29, 36, 40, 43, 78, 150–152
receptor tyrosine kinases (RTKs) 232, 236–237, 240, 245
regions, homopolymer 102, 104, 107
resection, surgical 46, 59, 62, 141–142
resistance 65, 74, 190, 193–195, 213, 233, 235, 237–240, 243–244
rolling circle amplification (RCA) 109, 218
RTKs, *see* receptor tyrosine kinases

SBL, *see* sequencing by ligation
SBS, *see* sequencing by synthesis
sensitivity 19, 40, 61–63, 65, 75, 90, 130, 142, 195, 207–208, 211, 213, 217–218, 241, 244
  clinical 39, 44, 75, 89
sentinel lymph nodes (SLNs) 61
sequence 19, 38, 40, 48, 107, 114–115, 119
sequence variations 36–37, 39, 66
sequencing by ligation (SBL) 99, 108
sequencing by synthesis (SBS) 99–101, 104, 106
sequencing chips 105–107
single-molecule real-time (SMRT) 99, 109
single-nucleotide variants (SNVs) 32, 102
SLNs, *see* sentinel lymph nodes
SMRT, *see* single-molecule real-time

SNVs, *see* single-nucleotide variants
solid tumors 41, 152–153, 163–164, 167, 207, 220
subculture 158–159
subgroups 1, 61, 182–183, 185, 234
  biomarker-defined 181
  biomarker-positive 174
supplement approvals 2, 16
survival 140, 176, 193, 233, 235, 237

third-generation sequencing 99, 109, 116, 119–120
tissue biopsies 79, 89, 233, 243
tissues, frozen 142–143
TKIs, *see* tyrosine kinase inhibitors
TNM, *see* tumor-node-metastasis
TPS, *see* tumor proportion score
transcript level 213–214
trastuzumab 2, 20, 118, 129, 134, 138, 206
treatment arms 174–176
treatment randomization 177–179
trial designs 173–174, 179–181, 183, 185
tumor cells 21, 61–63, 131–132, 139–140, 142, 150, 154–159, 161
  intraperitoneal 63
tumor culture 150, 161
tumor development 73, 76, 78
tumor-node-metastasis (TNM) 58
tumor proportion score (TPS) 138–141
tumor tissues 60, 144, 149–150, 152–153, 168, 241, 243
tumor types 74, 89, 143, 166–168, 220
tyrosine kinase inhibitors (TKIs) 165, 206–207, 210–211, 221, 231–232

variant types 20, 36–37, 41, 50
viral infections 64–65

WGS, *see* whole genome sequencing
whole genome sequencing (WGS) 40, 50, 98, 108, 116, 119–121

"Companion Diagnostics in Precision Medicine *is a comprehensive book that will be of tremendous help in developing anti-cancer therapeutics and accompanying diagnostics. It's the result of the herculean effort put in by the authors, and as a patient/survivor of lung cancer I know just how important this work is firsthand.*"

Bonnie Addario
Lung Cancer Survivor
Founder and Chair, Bonnie J. Addario Lung Cancer Foundation (ALCF)

"*Dr. Kim and coauthors provide a comprehensive review of the field of companion diagnostics, and their evolution from protein-based approaches to identification of genetic and genomic variants that optimize cancer care by identifying patients likely to respond to agents targeting specific molecular pathways relevant to their cancer. They further discuss clinical designs for approval and next-generation approaches, including proteomics and circulating tumor DNA that make this book an essential reference in the modern age of cancer drug development.*"

Dr. Charles Theuer
President and CEO, TRACON Pharmaceuticals

There is a new trend in anti-cancer therapeutics development: a targeted therapy and precision medicine that targets a subgroup of patients with specific biomarkers. An in vitro diagnostic (IVD) assay is required to identify a subgroup of cancer patients who would benefit from the targeted therapy, or not likely benefit, or have a high risk of side effects from the specific drug treatment. This IVD or medical device is called a companion diagnostic (CDx) assay. It is key to have a robust CDx assay or device for the success of targeted therapy and precision medicine.

This book covers the technical, historical, clinical, and regulatory aspects of CDx in precision medicine. Clearly, more and more newly developed oncology drugs will require accompanying CDx assays, and this book, with chapters contributed by renowned oncologists, provides a comprehensive foundation for the knowledge and application of CDx for precision medicine.

Il-Jin Kim (DVM, PhD, PMP, BCMAS, CCRP) was director of Applied Genomics in the UCSF Thoracic Oncology Program and is now medical director at Guardant Health, USA. He is an expert in cancer biomarker and companion diagnostics (CDx) for anti-cancer therapeutics (solid and hematological malignancies). His work focuses on the identification of novel therapeutic targets and diagnostic markers in various types of human cancers. Dr. Kim has received three awards from the American Association for Cancer Research for developing innovative diagnostic assays. He is a recipient of the 2017 Asclepios Award from the Bonnie J. Addario Lung Cancer Foundation.

V331
ISBN 978-981-4800-23-5
9 789814 800235

PAN STANFORD PUBLISHING
www.panstanford.com